サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1795343

サルコイドーシス治療薬の世界市場

Sarcoidosis Therapeutics

出版日
ページ情報
英文 175 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.53円
サルコイドーシス治療薬の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 175 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

サルコイドーシス治療薬の世界市場は2030年までに3億8,500万米ドルに達する見込み

2024年に3億240万米ドルと推定されるサルコイドーシス治療薬の世界市場は、2030年には3億8,500万米ドルに達し、分析期間2024～2030年のCAGRは4.1%で成長すると予測されます。本レポートで分析したセグメントの1つである副腎皮質ステロイド治療薬は、CAGR 3.1％を記録し、分析期間終了までに2億2,730万米ドルに達すると予測されます。その他の治療薬タイプセグメントの成長率は、分析期間中CAGR 5.7%と推定されます。

米国市場は7,950万米ドルと推定、中国はCAGR 4.1％で成長予測

米国のサルコイドーシス治療薬市場は、2024年に7,950万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを4.1%として、2030年までに6,240万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.6％と3.7％と予測されています。欧州では、ドイツがCAGR 3.5%で成長すると予測されています。

世界のサルコイドーシス治療薬市場- 主要動向と促進要因のまとめ

サルコイドーシスの治療状況における進歩の原動力は？

サルコイドーシスは、原因不明の複雑な多臓器炎症性疾患であり、過去10年間、治療法の選択肢は漸進的ではあるが有意義な進歩を遂げてきました。肺、リンパ節、皮膚、眼に好発する非カゼイチン性肉芽腫を特徴とするサルコイドーシスは、その不均一性、進行の多様性、病態生理の乏しさから、依然として治療が困難な疾患です。プレドニゾンのようなグルココルチコイドは、その抗炎症効果により長い間第一選択の治療薬として用いられてきました。しかし、コルチコステロイドの長期使用に伴う副作用（骨粗鬆症、高血糖、体重増加など）により、コルチコステロイドを温存する戦略への関心が高まっています。

メトトレキサート、アザチオプリン、レフルノミドなどの免疫抑制剤の第二選択薬は、慢性でコルチコステロイド抵抗性の症例に支持されています。さらに最近では、特定の免疫経路を標的とする生物学的薬剤が有望な治療手段として浮上してきました。インフリキシマブやアダリムマブなどの腫瘍壊死因子α（TNF-α）阻害薬は、難治性サルコイドーシス、特に神経サルコイドーシスや皮膚サルコイドーシスを含む肺外症状において有効性を示しています。エビデンスに基づくガイドラインの拡充、臨床試験データの増加、専門医の意識の高まりにより、治療プロトコールが再構築され、サルコイドーシスの管理により個別化された段階的アプローチが奨励されています。

新たな治療法と的を絞った介入は、疾患管理をどのように再構築しているのか？

サルコイドーシス治療薬の将来は、全体的な免疫機能を低下させることなく、免疫反応の特定の構成要素を調節する標的療法の開発にあります。最近の臨床試験では、肉芽腫形成、T細胞シグナル伝達、線維化経路を阻害する薬剤が検討されています。トファシチニブやルキソリチニブなどのヤヌスキナーゼ（JAK）阻害薬は、炎症性サイトカインを抑制し、ステロイド抵抗性サルコイドーシスの病勢進行を阻止する能力について研究中です。IL-6阻害薬やIL-12/23阻害薬などのインターロイキン標的治療薬も、より良好な安全性プロファイルで全身性炎症を抑制する潜在的有効性を求めて研究されています。

ニンテダニブやピルフェニドンなどの抗線維化剤は特発性肺線維症で承認されているが、進行性線維化を伴う肺サルコイドーシス症例での有用性が評価されています。これらの候補薬は、炎症抑制から肺構造温存への治療思考の転換を意味します。一方、分子プロファイリングとバイオマーカー探索の進歩は、臨床医が疾患表現型と治療反応性に基づいて患者をより適切に層別化することを可能にしています。このような精密医療のアプローチは、試行錯誤的な処方を減らし、長期的な転帰を改善すると期待されています。薬剤の再利用戦略も勢いを増しており、適応臨床試験デザインや実世界のエビデンスデータベースを通じて、既存の免疫調節薬がサルコイドーシスに対して再評価されています。

市場拡大に影響を与えている患者集団と地域動向は？

サルコイドーシスは地理的、人種的、人口統計学的に顕著なばらつきがあり、それが市場の需要や治療法に影響を及ぼしています。サルコイドーシスは、アフリカ系アメリカ人、特に20～40歳の女性の間で有病率が高く、重症で慢性的なサルコイドーシスを経験することが多いです。スカンジナビア、ドイツ、日本では、心臓および眼症状を伴う症例が多く、明確な罹患クラスターが報告されています。米国では、最近のヘルスケア改革とデジタルヘルスの取り組みにより、専門医へのアクセスが改善され、より早期の診断と介入が可能になりました。しかし、保険未加入者や農村部では格差が残っており、サルコイドーシスはしばしば過小診断や誤った管理下に置かれています。

欧州では、共同研究ネットワークと集中登録により、標準化された疾患の特徴が明らかにされ、多施設共同試験が促進されています。ドイツ、オランダ、英国は、この分野における臨床研究の主要な貢献国です。日本では、眼サルコイドーシスの症例が増加しており、眼科医主導の治療介入が行われています。中低所得国では、高度な画像診断や生検施設へのアクセスが限られているため、認知度や診断が低いままです。しかし、診断能力が向上し遠隔医療が拡大するにつれて、新興市場はサルコイドーシス治療、特に経口免疫抑制剤と費用対効果の高い生物学的製剤の世界的需要にますます貢献するようになると予想されます。

サルコイドーシス治療薬市場の成長を加速する主な促進要因は？

サルコイドーシス治療薬市場の成長は、アンメット・クリニカル・ニーズ、生物学的製剤や低分子の出現、診断プロトコルの改善など、いくつかの連動した要因によってもたらされます。従来のコルチコステロイドに基づく管理は、短期的には有効であるが、長期的にはかなりのリスクを伴うため、より安全で標的を絞った代替薬が臨床的に求められています。慢性サルコイドーシス、特に肺サルコイドーシスと心サルコイドーシスの負担が増加していることから、全身毒性を最小限に抑え、臓器機能を維持する先進的な治療薬に対する需要が高まっています。臨床医の意識の高まりは、疾患特異的治療アルゴリズムの普及と相まって、より積極的で個別化された介入戦略を促しています。

医薬品イノベーションと希少炎症性疾患研究への戦略的投資により治療パイプラインが拡大し、北米と欧州で複数の第II相および第III相試験が進行中です。規制機関は、希少疾病用医薬品の指定、迅速承認、研究助成金を提供し、この顧みられない領域における技術革新にインセンティブを与えています。実際のエビデンスプラットフォームや患者登録は、疾患の進行、治療効果、ヘルスケア利用についての洞察を提供し、市場拡大の指針となっています。さらに、呼吸器専門医、リウマチ専門医、皮膚科専門医、神経科専門医による領域横断的な連携が、サルコイドーシス治療のより総合的な見方を促進し、多様なヘルスケアシステムにおける統合治療モデルと治療普及への道を開いています。

セグメント

タイプ（副腎皮質ステロイド治療薬、その他の治療薬タイプ）、流通チャネル（病院薬局、小売薬局、オンライン流通チャネル）

調査対象企業の例

  • AbbVie Inc.
  • Adaptimmune Therapeutics Plc
  • Amgen Inc.
  • aTyr Pharma Inc.
  • Bellus Health Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Foresee Pharmaceuticals Co. Ltd.
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Kinevant Sciences GmbH
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Molecure S.A.
  • Novartis AG
  • Pfizer Inc.
  • Relief Therapeutics Holding SA
  • Xentria Inc.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP37967

Global Sarcoidosis Therapeutics Market to Reach US$385.0 Million by 2030

The global market for Sarcoidosis Therapeutics estimated at US$302.4 Million in the year 2024, is expected to reach US$385.0 Million by 2030, growing at a CAGR of 4.1% over the analysis period 2024-2030. Corticosteroids Therapeutics, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$227.3 Million by the end of the analysis period. Growth in the Other Therapeutics Types segment is estimated at 5.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$79.5 Million While China is Forecast to Grow at 4.1% CAGR

The Sarcoidosis Therapeutics market in the U.S. is estimated at US$79.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$62.4 Million by the year 2030 trailing a CAGR of 4.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 3.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.5% CAGR.

Global Sarcoidosis Therapeutics Market - Key Trends & Drivers Summarized

What Is Fueling the Advancements in the Therapeutic Landscape for Sarcoidosis?

Sarcoidosis, a complex multisystem inflammatory disease of unknown etiology, has seen incremental yet meaningful advancements in therapeutic options over the past decade. Characterized by non-caseating granulomas that predominantly affect the lungs, lymph nodes, skin, and eyes, sarcoidosis remains challenging to treat due to its heterogeneity, variable progression, and poorly understood pathophysiology. Glucocorticoids such as prednisone have long served as first-line treatments due to their anti-inflammatory efficacy. However, the adverse effects associated with prolonged corticosteroid use-including osteoporosis, hyperglycemia, and weight gain-have led to growing interest in corticosteroid-sparing strategies.

Second-line immunosuppressive agents such as methotrexate, azathioprine, and leflunomide have gained traction for chronic and corticosteroid-refractory cases. More recently, biological agents targeting specific immune pathways have emerged as promising therapeutic avenues. Tumor necrosis factor-alpha (TNF-α) inhibitors such as infliximab and adalimumab have shown efficacy in refractory sarcoidosis, especially in extrapulmonary manifestations including neurosarcoidosis and cutaneous sarcoidosis. The expansion of evidence-based guidelines, growing clinical trial data, and increasing awareness among specialists are reshaping treatment protocols and encouraging a more individualized, stepwise approach to managing sarcoidosis.

How Are Emerging Therapies and Targeted Interventions Reshaping Disease Management?

The future of sarcoidosis therapeutics lies in the development of targeted therapies that modulate specific components of the immune response without compromising overall immune function. Recent clinical trials are exploring agents that interfere with granuloma formation, T-cell signaling, and fibrotic pathways. Janus kinase (JAK) inhibitors, such as tofacitinib and ruxolitinib, are under investigation for their ability to suppress pro-inflammatory cytokines and halt disease progression in steroid-resistant sarcoidosis. Interleukin-targeted therapies, including IL-6 and IL-12/23 inhibitors, are also being studied for potential efficacy in reducing systemic inflammation with a more favorable safety profile.

Antifibrotic agents like nintedanib and pirfenidone-originally approved for idiopathic pulmonary fibrosis-are being evaluated for their utility in pulmonary sarcoidosis cases with progressive fibrosis. These candidates represent a shift in therapeutic thinking from inflammation suppression to structural lung preservation. Meanwhile, advances in molecular profiling and biomarker discovery are enabling clinicians to better stratify patients based on disease phenotype and treatment response. This precision medicine approach is expected to reduce trial-and-error prescribing and improve long-term outcomes. Drug repurposing strategies are also gaining momentum, with existing immunomodulators being reassessed for sarcoidosis via adaptive clinical trial designs and real-world evidence databases.

Which Patient Populations and Regional Trends Are Influencing Market Expansion?

Sarcoidosis exhibits notable geographic, racial, and demographic variability, which in turn influences market demand and treatment practices. The disease has higher prevalence among African American populations, particularly women aged 20-40, who often experience more severe and chronic forms of sarcoidosis. Scandinavia, Germany, and Japan report distinct incidence clusters, with more cases involving cardiac and ocular manifestations. In the United States, recent healthcare reforms and digital health initiatives have improved access to specialist care, allowing for earlier diagnosis and intervention. However, disparities remain in underinsured and rural populations, where sarcoidosis often goes underdiagnosed or mismanaged.

In Europe, collaborative research networks and centralized registries are enabling standardized disease characterization and fostering multicenter trials. Germany, the Netherlands, and the UK are leading contributors to clinical research in this area. Japan is witnessing a rise in ocular sarcoidosis cases, prompting more ophthalmologist-led therapeutic interventions. In low- and middle-income countries, awareness and diagnosis remain low due to limited access to advanced imaging and biopsy facilities. However, as diagnostic capabilities improve and telemedicine expands, emerging markets are expected to contribute increasingly to the global demand for sarcoidosis therapies, especially for oral immunosuppressants and cost-effective biologics.

What Are the Key Drivers Accelerating Growth in the Sarcoidosis Therapeutics Market?

The growth in the sarcoidosis therapeutics market is driven by several interlinked factors, including unmet clinical needs, the emergence of biologics and small molecules, and improved diagnostic protocols. Traditional corticosteroid-based management, while effective in the short term, carries substantial long-term risk, creating a clinical imperative for safer, targeted alternatives. The increasing burden of chronic sarcoidosis, particularly in pulmonary and cardiac forms, is propelling demand for advanced therapeutics that minimize systemic toxicity and preserve organ function. Rising awareness among clinicians, coupled with the proliferation of disease-specific treatment algorithms, is encouraging more aggressive and tailored intervention strategies.

Pharmaceutical innovation and strategic investments in rare inflammatory disease research are expanding the therapeutic pipeline, with multiple Phase II and III trials underway across North America and Europe. Regulatory agencies are offering orphan drug designations, fast-track approvals, and research grants to incentivize innovation in this neglected space. Real-world evidence platforms and patient registries are providing insights into disease progression, treatment effectiveness, and healthcare utilization, helping guide market expansion. Moreover, cross-disciplinary collaboration among pulmonologists, rheumatologists, dermatologists, and neurologists is fostering a more holistic view of sarcoidosis care, paving the way for integrated treatment models and expanded therapeutic uptake across diverse healthcare systems.

SCOPE OF STUDY:

The report analyzes the Sarcoidosis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Corticosteroids Therapeutics, Other Therapeutics Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • AbbVie Inc.
  • Adaptimmune Therapeutics Plc
  • Amgen Inc.
  • aTyr Pharma Inc.
  • Bellus Health Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb
  • Foresee Pharmaceuticals Co. Ltd.
  • GSK plc
  • Hikma Pharmaceuticals PLC
  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Kinevant Sciences GmbH
  • Kyorin Pharmaceutical Co., Ltd.
  • Mallinckrodt plc
  • Merck & Co., Inc.
  • Molecure S.A.
  • Novartis AG
  • Pfizer Inc.
  • Relief Therapeutics Holding SA
  • Xentria Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Sarcoidosis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Granulomatous Diseases Throws the Spotlight on Sarcoidosis Therapeutics
    • Increased Awareness and Early Diagnosis Spur Demand for First-Line Anti-Inflammatory Treatments
    • Expansion of Multisystemic Disease Understanding Strengthens Business Case for Multimodal Therapy
    • Advances in Immunomodulatory Agents Propel Development of Targeted Sarcoidosis Therapies
    • Growing Use of Biologics in Refractory Sarcoidosis Accelerates Pipeline Innovation
    • Development of Corticosteroid-Sparing Strategies Generates Demand for Novel Mechanisms of Action
    • Increased Application of Personalized Medicine Approaches Expands Therapeutic Customization
    • Collaborative Research Initiatives With Rare Disease Networks Fuel Clinical Data Generation
    • Expansion of Real-World Evidence Databases Strengthens Market Access and Reimbursement Justifications
    • Growing Recognition of Cardiac and Neurosarcoidosis as Distinct Subtypes Expands Therapeutic Scope
    • Regulatory Support for Orphan Drug Designations Accelerates Development Timelines
    • Integration of Digital Biomarkers and Imaging Tools Enhances Monitoring of Disease Progression
    • Rising Participation in Multinational Clinical Trials Boosts Global Product Development Pipelines
    • Demand for Multidisciplinary Treatment Approaches Drives Cross-Specialty Therapeutic Strategies
    • Increased Focus on Patient-Reported Outcomes and Quality of Life Metrics Supports Value-Based Pricing
    • Availability of Compassionate Use Programs Enhances Market Entry for Investigational Products
    • Partnerships Between Pharma and Academia Strengthen Translational Research in Autoimmune Diseases
    • Expansion of Health Policy Support in Rare and Underdiagnosed Diseases Propels Market Recognition
    • Growth in Biopharmaceutical Investment in Inflammatory and Fibrotic Pathways Fuels Sarcoidosis R&D
    • Advances in Pulmonary and Systemic Sarcoidosis Classification Enhance Therapeutic Targeting
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Sarcoidosis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Sarcoidosis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Sarcoidosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Corticosteroids Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Corticosteroids Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Corticosteroids Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Therapeutics Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Other Therapeutics Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Other Therapeutics Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Sarcoidosis Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Sarcoidosis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 77: Rest of Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Rest of Europe Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 79: Rest of Europe 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Sarcoidosis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 83: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Asia-Pacific Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 85: Asia-Pacific 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF WORLD
    • TABLE 89: Rest of World Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of World Historic Review for Sarcoidosis Therapeutics by Type - Corticosteroids Therapeutics and Other Therapeutics Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of World 16-Year Perspective for Sarcoidosis Therapeutics by Type - Percentage Breakdown of Value Sales for Corticosteroids Therapeutics and Other Therapeutics Types for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Sarcoidosis Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Sarcoidosis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION